West-Nile virus replicon particles infect 293T cells expressing DC-SIGNR
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Introduction
Since its migration to New York in 1999, a strain of West-Nile Virus (WNV) that primarily
used a bird host and mosquito vector transmission cycle has swept across the western
hemisphere into Central and South America (1). Human WNV infection may lead to West
Nile fever, associated with symptoms that persist past 30 days in >60% of cases (1,2). In
addition, it has been estimated that ≈ 1 in 50 infected patients ≥65 years develop
encephalitis, meningitis, and paralysis (1, 3). Since, presently, there exist no accepted
human vaccine, vector preventive measures serve as the primary avenue for combating
primary infection. Current treatments are mostly supportive (1).
Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin Related
protein (DC-SIGNR) on lung, lymph, and liver endothelia when expressed on a cell line,
enhanced WNV infection (4) as well as related Flaviviruses Japanese encephalitis virus(5)
and dengue virus(6). Davis (2006) proposed that N-linked high-mannose oligosaccharides
primarily on WNV transmembrane protein E have multivalent interactions with the
carbohydrate recognition domain (CRD) of DC-SIGNR as both anti-CRD antibodies and E
protein gene knockout reduced infection to levels comparable to control cell lines.
Further research will identify which amino acids are important for DC-SIGNR-dependent
WNV infection. DC-SIGN, a related molecule of DC-SIGNR, enhances Flavivirus entry and
the C-Terminus half of its CRD is primarily responsible for this enhancement (5, 6, 7).
Although similar, the CRD of DC-SIGN and DC-SIGNR have different ligand molecular
interactions (7). The purpose of this study is to test whether WNV entry requires the Cterminal half of the CRD of DC-SIGNR.
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Figure 2. Lab produced VRPs are used to safely test
viral infection. Transfection of two plasmids into HEK293T cells leads to the production of WNV VRPs. One
plasmid expresses the structural membrane, capsid,
and attachment proteins; PrM, C, and E, respectively.
While the other plasmid contains a green fluorescent
protein (GFP) expressed from within a mutated viral
genome. The structural proteins and GFP containing
genome assemble to create a non-replicating infectious
WNV virions.
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Generating DC-SIGNR expressing cells with mutations
DC-SIGNR 7

Figure 3. To generate stable expressing DC-SIGNR from
normally non-expressing HEK-293T cells, the open
reading frames of DC-SIGNR7 was subcloned into SBPmini vector. The SBP-mini vector co-expresses a
streptavidin-binding mini protein on the cell surface as
well as hygromycin resistance which was used to select
out stable cells. Mutations were made to DC-SIGNR7.
The CRD-1 mutation removed the carbohydrate
recognition domain and the CRD-2 mutation removed
half of the domain. These mutants were also used to
generate CRD-1 and CRD-2 stably expressing 293T
cells.
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Figure 4. DC-SIGNR expression on 293T
cells. All cells (293T expressing nothing,
DC-SIGNR, 293T cells expressing DCSIGNR CRD1 and 293T cells expressing
DC-SIGNR CRD2) were stained with antiDC-SIGNR monoclonal antibody,
polyclonal anti-DC-SIGNR antibody and
finally a monoclonal antibody that stains
only the CRD in DC-SIGNR. The light
colored histogram represents stained
293T cells expressing nothing.
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Figure 1. The WNV virion attachment E protein in part determines the tropism of the virus

by attaching to target cell surface receptors.
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These results show that WNV VRPs infect 293T DC-SIGNR expressing cells. Eliminating the
CRD or the C-terminal portion of the CRD ablates efficient entry into the 293T cells. We
also show that eliminating the CRD from DC-SIGNR does not prevent the mutant’s cell
surface expression (Figure 4) and therefore the lack of entry by the WNV VRPs is not due
to lack of cell surface expression of the protein. Altogether, these results demonstrate
that the CRD is critical for viral entry and suggest that the virus may specifically bind to
DC-SIGNR via the C-terminal portion of the CRD. Further experiments will be performed
to identify those amino acids in DC-SIGNR responsible for mediating entry of the WNV.
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Surface expression of DC-SIGNR and its mutants
Figure 5. WNV uses the E
attachment protein to bind to
a target cell. If the virus gains
entry into the cell, it releases
its viral genome into the
cytoplasm of the target cell.
GFP is expressed from the
modified genome and the cell
fluoresces green.
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Figure 6. WNV entry requires the C-terminal half of the CRD of DC-SIGNR. 293T, 293T
expressing DC-SIGNR, DC-SIGNR CRD1 (DCRD) and DC-SIGNR CRD (DCRD2) were plated
in 96 well plates and infected in triplicate with control, WNV (NY99) containing betalactamase and WNV (NY99) for three days. Green fluorescent foci were manually
counted from each of the three infection wells and graphed above.
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West-Nile virus (WNV) is an arbovirus usually transmitted to humans via a mosquito
vector. Infections commonly result in febrile symptoms while rare severe neuroinvasive
cases may result in encephalitis or meningitis. Studies have shown that WNV infection
efficiency is enhanced by expression of DC-SIGNR on target cells, which normally do not
express DC-SIGNR. To investigate WNV tropism, we established 293T kidney epithelial cell
lines that stably express vector, DC-SIGNR and mutants of DC-SIGNR that lack the entire
carbohydrate-recognition domain (CRD) or lack the C-terminal half of the CRD. We
demonstrate successful surface expression of DC-SIGNR and its mutants from stablytransfected 293T cells, but not vector-transfected 293T cells. Further, we show that
monoclonal antibody 120604 which binds specifically to the DC-SIGNR CRD binds to DCSIGNR expressing 293T cells, but not to vector nor any of the DC-SIGNR mutants
expressing cells. Virus replicon particles (VRPs), replication-incompetent viral particles
containing necessary structural proteins for infection and a viral plasmid including a GFP
reporter are used to safely and conveniently study viral entry. Entry assays using WNV
(NY99) VRPs as well as a variant of WNV (NY99) which contains the beta-lactamase
enzyme show significant entry into DC-SIGNR expressing cell lines, but not in controls that
do not express DC-SIGNR. Additionally, we show that WNV VRPs do not enter DC-SIGNR
expressing cells that lack the CRD or the C-terminal half of the CRD suggesting that the Cterminal half of the CRD is required for successful entry of WNV via DC-SIGNR. Future
experiments may be able to shed light on which amino acids are required for entry.
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